NASDAQ: RYTM

Rhythm Pharmaceuticals (RYTM) Stock Analysis & Forecast

Nov 13 close

$115.02+5.16 (+4.7%)

Gekko Brief

AI summaryNov 9 close

Rhythm Pharmaceuticals has been dominated this week by takeover speculation, with reports that AstraZeneca made an approximately $10 billion offer to acquire the company, valued at up to $134 per share including milestone payments, and initial reports of a $124-a-share bid. Shares jumped 28% on the news, and subsequent reports of a second bidder, speculated to be a large pharmaceutical company, added a further 4.2% move. Alongside the deal talk, JP Morgan maintained an Overweight rating while trimming its target to $142 from $145, and Guggenheim maintained Buy while raising its target to $147 from $143. A separate commentary flagged the stock's price-to-sales ratio of 27.7x as stretched following a new $750 million term loan and an amended license for bivamelagon.

The stock closed at $113.94, up 1.5% on the day, sitting above both its 50-day average of $96.29 and 200-day average of $97.06, with a one-month return of 25.5% and a six-month return of 30.4%. The GekkoIndex reads 41.1, placing it in the Distribution zone, down 15.7 over the past five readings. Price sits just 0.1% above Gekko Fair Value of $113.81.

The next earnings date is 25 February 2027, 107 days out, beyond a typical 20-trading-day swing window. Over the last 30 days there has been 1 unusual options signal, with call premium of $465,115 against no put premium. One billionaire holder is recorded. Seasonally, the next 20 trading days have averaged +5.7% over 5 years, rising in 3 of them. Analyst consensus stands at 13 buy, 1 hold, 0 sell, with a consensus target of $140.29.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Rhythm Pharmaceuticals price vs fair value

$115.02$114.18Nov ’25May ’26Nov ’26
Close $115.02200-day averageGekko Fair Value $114.18

Rhythm Pharmaceuticals quick facts

Market cap
$7.97B
P/E ratio
—
Forward P/E
333.3
EPS, TTM
−$2.91
Revenue, TTM
$280.7M
Profit margin
-69%
Dividend yield
—
Beta
2.13
Volume
1.14M avg 1.77M
1-year return
+17.5%
Typical daily move
±5.7%
Typical 20-day move
±10.3%
50-day average
$96.88
200-day average
$97.24
Next earnings
Feb 25 before open
Shares outstanding
69.33M
52-week range
$74.50$122.20

Rhythm Pharmaceuticals swing-trade checklist

Rhythm Pharmaceuticals scores 3 supportive, 3 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive3 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $115.02 sits between the 50-day ($96.88) and 200-day ($97.24) averages, or the averages disagree.

    See the chart
  • GekkoIndexmixed

    46.7, Neutral

    Reading 46.7 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    0.7% above

    Price is within 5% of Gekko Fair Value (0.7% above).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 2 unusual options signals.

    See smart money
  • Earnings risksupportive

    Reports in 102 days

    Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +3.7% on average

    From this point in the calendar, the next 20 trading days averaged +3.7% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Rhythm Pharmaceuticals stock chart and price history

Rhythm Pharmaceuticals closed at $115.02 on Nov 13, 2026, +17.5% over the past year, inside a 52-week range of $74.50 to $122.20.

Close50-day average200-day averageVolume
Rhythm Pharmaceuticals share price, past year, with 50-day and 200-day moving averages and volume$80$90$100$110$120DecJan 2026FebMarAprMayJunJulAugSepOctNov115.02

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+30.7%
3 months
−0.4%
6 months
+27.1%
1 year
+17.5%
The full RYTM chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RYTM in Gekko

Follow Rhythm Pharmaceuticals through every session

Put RYTM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track RYTM in GekkoFree for 7 days. No credit card required.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals works on medicines for rare genetic disorders that lead to obesity, combining research, development and the sale of approved treatments. Its main product, IMCIVREE, acts on the melanocortin-4 receptor pathway and is used for obesity linked to POMC, PCSK1 or LEPR deficiencies, as well as for patients with Bardet-Biedl and Alström syndromes. This treatment forms the core of what the company is recognized for in the market.

Beyond its marketed therapy, the company is studying the same active compound, setmelanotide, in Phase II trials aimed at additional conditions, including heterozygous POMC or LEPR deficiency, SRC1 and SH2B1 deficiencies, MC4 receptor deficiency, and obesity tied to Smith-Magenis syndrome and related POMC epigenetic disorders. It also participates in a collaborative research arrangement with the Clinical Registry Investigating Bardet-Biedl Syndrome, connecting its pipeline work to patients affected by these conditions.

The company is based in Boston, Massachusetts, and traces its founding to 2008, having operated originally under the name Rhythm Metabolic before adopting its current name in 2015. Its shares are listed on the NASDAQ under the ticker RYTM.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
rhythmtx.com

Rhythm Pharmaceuticals GekkoIndex: the smart money zone

Rhythm Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 46.7, in the Neutral zone, up 3.6 points over five sessions.

010046.7Neutral

Up 3.6 points over five sessions, from the Distribution zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying16+0.3%−0.2%+4.7%+22.0%
Accumulation219+1.8%+2.7%+3.1%+6.9%
Neutral (current zone)416+0.7%+1.6%+3.4%+9.0%
Distribution44−1.2%−2.3%−4.3%−0.8%
Selling7Too few readings yet

Average RYTM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the RYTM price, zone by zone.Track RYTM in Gekko

Is Rhythm Pharmaceuticals stock overvalued? Gekko Fair Value

Rhythm Pharmaceuticals trades 0.7% above Gekko Fair Value of $114.18, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Rhythm Pharmaceuticals shares are worth, recalculated every trading day.

$114.18

Gekko Fair Value, Nov 14, 2026

0.7% above fair value · About fair value

At the end of Aug 2026 the price was 18.0% below the estimate.

Gekko Fair ValueShare price, month end
$114$115Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open RYTM in Gekko

Rhythm Pharmaceuticals insider and Congress trading

No open-market insider purchases were filed for Rhythm Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for RYTM in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every RYTM insider filing, plotted on the chart in Gekko.Open RYTM in Gekko

Congress trades last 90 days

No trades in RYTM were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for RYTM, plotted on the chart in Gekko.Open RYTM in Gekko

Unusual options activity last 30 days

2signals, 100% of the flagged premium in calls.

Latest: Bullish flow on Nov 14, $403K in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds RYTM.

0added1opened0trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Rhythm Pharmaceuticals earnings: next date and track record

Rhythm Pharmaceuticals reports on Feb 25, 2027, before the open (102 days away), and beat the EPS estimate in 4 of its last 8 reports.

4 of 8reports beat the EPS estimate
±8.2%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+3.9%Feb ’25−3.2%May ’25−0.3%Aug ’25−12.5%Nov ’25−6.5%Feb ’26+12.9%May ’26+7.7%Aug ’26+18.5%Nov ’26

Last earnings call, Nov 3, 2026 AI summary

What they said
Rhythm Pharmaceuticals reported Q3 2026 revenue of $92 million, driven by strong U.S. launch performance with growing start forms and favorable market access. Japan commercial launch is underway with first patients on treatment, expected to become the second-largest market. Strategic pillars include genetic indications, hypothalamic obesity (HO), and Prader-Willi syndrome (PWS), with Phase III trials planned using bivamelagon for PWS.
Guidance
Management expects Japan to become their second-largest market. PWS Phase III trial with bivamelagon is planned, with next-generation therapies RM-718 also in development for PWS. Additional portfolio and pipeline details are expected to be disclosed in 2027.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 3, 2026−$0.61
est −$0.71
+14.0%$92.13M
est $85.57M
+7.7%+18.5%
Aug 4, 2026−$0.73
est −$0.81
+9.6%$71.26M
est $67.66M
+5.3%+7.7%
May 5, 2026−$0.83
est −$0.86
+3.5%$60.11M
est $55.78M
+7.8%+12.9%
Feb 26, 2026−$0.73
est −$0.79
+7.6%$57.25M
est $56.21M
+1.9%−6.5%
Nov 4, 2025−$0.82
est −$0.72
−13.9%$51.30M
est $55.98M
−8.4%−12.5%
Aug 5, 2025−$0.75
est −$0.66
−13.6%$48.50M
est $51.33M
−5.5%−0.3%
May 7, 2025−$0.81
est −$0.69
−17.4%$32.70M
est $43.28M
−24.4%−3.2%
Feb 26, 2025−$0.72
est −$0.69
−4.3%$41.83M
est $38.48M
+8.7%+3.9%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Rhythm Pharmaceuticals stock forecast and analyst price targets

Analysts’ average 12-month price target for Rhythm Pharmaceuticals is $140.12, +21.8% from the last close, from 14 firms rating the stock in the last 90 days.

$140.12consensus 12-month target, +21.8% from the last close
Low $120High $206
Buy13
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 14 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 5Canaccord GenuityBuy, maintained$168+46.1%
Nov 5CitiBuy, reiterated$143+24.3%
Nov 4Citizens JMPBuy, maintained$166+44.3%
Nov 4Morgan StanleyBuy, maintained$146+26.9%
Nov 4Wells FargoBuy, reiterated$155+34.8%
+3.4%average 20-day move after past Neutral readings
+3.7%average move over the next 20 trading days in the last 5 years
±5.7%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Rhythm Pharmaceuticals seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Rhythm Pharmaceuticals averaged +3.7% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−28.2%2021+14.8%2022+26.1%2023−7.6%2024+13.2%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−6.4%2 of 5
Next 10 trading days−5.5%2 of 5
Next 15 trading days−1.0%3 of 5
Next 20 trading days+3.7%3 of 5
Next 30 trading days+7.0%3 of 5

For scale, RYTM’s typical 20-trading-day move in either direction is about 10.3%.

Rhythm Pharmaceuticals market cap and key statistics

Rhythm Pharmaceuticals’s market cap is $7.97B and revenue of $280.7M over the last twelve months.

Valuation

Market cap
$7.97B
Forward P/E
333.3
EPS, TTM
−$2.91
Gekko Fair Value
$114.18

Trading

Volume
1.14M
Avg volume, 20 days
1.77M
52-week high
$122.20
52-week low
$74.50
Shares outstanding
69.33M

Financials

Revenue, TTM
$280.7M
Profit margin
-69%
Return on equity
-78%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
2.13
Typical daily move
±5.7%
Typical 20-day move
±10.3%

Rhythm Pharmaceuticals peers

Rhythm Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Rhythm Pharmaceuticals stock FAQ

What is Rhythm Pharmaceuticals’s market cap?

Rhythm Pharmaceuticals’s market cap is $7.97B at the Nov 13, 2026 close of $115.02, with 69.33M shares outstanding.

What is the Rhythm Pharmaceuticals stock forecast?

The consensus analyst 12-month price target for Rhythm Pharmaceuticals is $140.12, +21.8% from the last close. Of the 14 firms that rated the stock in the last 90 days, 13 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Rhythm Pharmaceuticals stock overvalued or undervalued?

On Gekko’s estimate Rhythm Pharmaceuticals is about fair value: the Nov 13, 2026 close of $115.02 is 0.7% above Gekko Fair Value of $114.18. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Rhythm Pharmaceuticals report earnings next?

Rhythm Pharmaceuticals is expected to report on Feb 25, 2027, before the market opens (102 days away). Analysts expect earnings of −$2.59 per share on revenue of $109.6M. Rhythm Pharmaceuticals beat the earnings estimate in 4 of its last 8 reports, moving 8.2% on average across the report.

What is Rhythm Pharmaceuticals’s 52-week high and low?

Rhythm Pharmaceuticals’s 52-week high is $122.20 and its 52-week low is $74.50; it closed at $115.02 on Nov 13, 2026, +17.5% over the past year.

Is Rhythm Pharmaceuticals stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (smart money, earnings risk and seasonality), 3 as mixed (trend, gekkoindex and fair value). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Rhythm Pharmaceuticals?

Gekko flagged 2 unusual options signals in Rhythm Pharmaceuticals over the last 30 days, with $868K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Nov 14, 2026 with $403K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Rhythm Pharmaceuticals the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.